---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-214262"
form_type: "8-K"
ticker: null
cik: "0001604950"
company_name: "scPharmaceuticals Inc."
filed_at: "2025-09-24T23:59:59+00:00"
generated_at: "2026-05-17T05:47:20.565238+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# scPharmaceuticals issues $10M promissory note to MannKind as bridge loan pending merger

## Summary
- Unsecured note for $10M issued to MannKind Corp. on Sept 23, 2025.
- Interest at 9.00467% initially, tied to MannKind's SOFR loan rate plus margin.
- Maturity on earliest of Sept 23, 2026, termination fee payment, or superior proposal close.
- Loan is in connection with the Aug 24, 2025 Merger Agreement for MannKind to acquire scPharmaceuticals.
- Covenants mirror existing Perceptive credit agreement; baskets for debt and liens increased 25%.

## SEC filing metadata
- accession: 0001193125-25-214262
- form_type: 8-K
- cik: 0001604950
- company_name: scPharmaceuticals Inc.
- filed_at: 2025-09-24T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604950/000119312525214262/0001193125-25-214262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604950/000119312525214262/d62041d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-214262
- JSON: https://secwatch.observer/filing/0001193125-25-214262.json
- Plain text: https://secwatch.observer/filing/0001193125-25-214262.txt

## Key facts
- Debt Financings
  scPharmaceuticals Inc. incurred loan of $10.0 million with MannKind Corporation at interest rate applicable to Parent for SOFR Loans under the Credit Agreement; pr maturing September 23, 2026.
  - Instrument: loan
  - Principal: $10.0 million
  - Counterparty: MannKind Corporation
  - Rate: interest rate applicable to Parent for SOFR Loans under the Credit Agreement; pr
  - Maturity: September 23, 2026
  - Event: incurrence
  source text: or “scPharmaceuticals”), issued an unsecured promissory note (the “Company Promissory Note”) to MannKind Corporation, a Delaware corporation (“Parent”) in exchange for a loan of $10.0 million by Parent to the Company. As previously disclosed, on August 24, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Parent and Seacoast
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604950/000119312525214262/0001193125-25-214262-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.